After many years of research have been developed, and then in January 2013 approved by the European Medicines Agency new multicomponent vaccine against meningococcal disease Group B Bexsero from Novartis. Meningococcal disease, because of its rapid progression and tragic consequences, a very dangerous disease. The aim of my thesis was to try to quantify the impact on the costs and benefits of the introduction of vaccination for the most vulnerable groups, namely children after birth to 4 years of age, by comparing the hypothetical vaccinated and unvaccinated cohorts. The work itself has not demonstrated at today's prices and epidemiological data Bexsero vaccines, cost efficiency. However, at a reduced cost or increased incidence of cases appear to vaccination Bexsero as well utilized resources.
| Identifer | oai:union.ndltd.org:nusl.cz/oai:invenio.nusl.cz:262200 |
| Date | January 2017 |
| Creators | Kříž, David |
| Contributors | Pažitný, Peter, Kandilaki, Daniela |
| Publisher | Vysoká škola ekonomická v Praze |
| Source Sets | Czech ETDs |
| Language | Czech |
| Detected Language | English |
| Type | info:eu-repo/semantics/masterThesis |
| Rights | info:eu-repo/semantics/restrictedAccess |
Page generated in 0.0022 seconds